IMO although the trial "failed" the primary efficacy endpoint, I...

IMO although the trial "failed" the primary efficacy endpoint, I think the best that can be said is that "on the basis of this 6 month trial we don't really know if NTcell works or not".

The final placebo reading at 26 weeks is the one that did the damage by bringing it too close to the 2nd cohort. Its pretty likely that at 52 weeks it will go back the other way. To be convincing I think perhaps the trial should have been 12 months and with 24 patients. Now what would need to happen is for sufficient divergence to occur between the placebo group and the other patients for the DSMB to allow the placebo patients to be implanted and the trial to complete.